Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
Hematological Oncology · 2024
DOI: 10.1002/hon.3222 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, 2024. Verfasst von Mohamed Badawi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, Inc, North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Neutropenia, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: AbbVie, Genentech.
Abstract (Originalsprache)
Venetoclax, a potent BCL‐2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure–response relationships of venetoclax for a phase 1/2 study evaluating venetoclax monotherapy or in combination with dexamethasone in relapsed or refractory MM. A total of 117 patients receiving venetoclax at 300, 600, 800, 900, or 1200 mg were included in the analysis. The impact of venetoclax exposures on efficacy (objective response rate [ORR], progression‐free survival [PFS] and overall survival [OS]) as well as safety (treatment‐emergent adverse effects (grade ≥3) of neutropenia, infection, and any grade of serious treatment‐emergent adverse effects) was evaluated. In the t(11;14)‐positive subpopulation, venetoclax exposure relationships to PFS and OS indicated a trend of longer PFS and OS with higher exposures. Moreover, logistic regression analyses for clinical response (ORR and ≥VGPR rate) demonstrated a statistically significant ( p < 0.05) relationship with exposure. Evaluation of the exposure‐safety relationships demonstrated a lack of a relationship between venetoclax exposures (AUC avg ) and grade ≥3 infections, grade ≥3 neutropenia, grade ≥3 treatment‐emergent adverse events or any grade serious treatment‐emergent adverse events. These findings support further study of venetoclax at 800 mg QD dose in combination with dexamethasone in the t(11;14)‐positive patient population where increased efficacy was observed without an increase in safety events.Clinical Trial: NCT01794520 registered 20 February 2013.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, AbbVie, Inc, North Chicago, Illinois, USA.
- Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen Am Rhein, Germany.
- Clinical Pharmacology, Genentech Inc, South San Francisco, California, USA.
- Clinical Development, Pharmacyclics Switzerland GmbH, An AbbVie Company, Schaffhausen, Switzerland.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Clinical Pharmacy, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Mohamed Badawi, Sheryl Coppola, Sathej Gopalakrishnan, Rajeev M Menon, Ahmed Hamed Salem
Förderung
- AbbVie
- Genentech
Zitieren
APA
Badawi, M., Coppola, S., Eckert, D., Gopalakrishnan, S., Engelhardt, B., Doelger, E., Huang, W., Dobkowska, E., Kumar, S., Menon, R. M., & Salem, A. H. (2024). Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. Hematological Oncology. https://doi.org/10.1002/hon.3222
Vancouver
Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E, et al. Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. Hematological Oncology. 2024. doi:10.1002/hon.3222
BibTeX
@article{Badawi2024,
author = {Badawi, Mohamed and Coppola, Sheryl and Eckert, Doerthe and Gopalakrishnan, Sathej and Engelhardt, Benjamin and Doelger, Eva and Huang, Weize and Dobkowska, Edyta and Kumar, Shaji and Menon, Rajeev M and Salem, Ahmed Hamed},
title = {Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3222}
}
EUVIMED